• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Monthly Archive for: "April, 2023"
 Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
 0
By Nascent Biotech
In Corporate News, News, Press Releases, Science News
Posted April 18, 2023

Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval

NORTH PALM BEACH, FL / ACCESSWIRE / April 18, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.